Issue 4/2017
Content (13 Articles)
Current status of achalasia management: a review on diagnosis and treatment
Joshua Tuason, Haruhiro Inoue
A critical overview on the biological and molecular features of red and processed meat in colorectal carcinogenesis
Arunan Jeyakumar, Lakal Dissabandara, Vinod Gopalan
Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma
Wenhui Wang, Qiuwei Pan, Gwenny M. Fuhler, Ron Smits, Maikel P. Peppelenbosch
Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial
Kyungsun Han, Jinghwa Wang, Jae-Gu Seo, Hojun Kim
Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn
Marzio Frazzoni, Nicola de Bortoli, Leonardo Frazzoni, Manuele Furnari, Irene Martinucci, Salvatore Tolone, Andrea Farioli, Santino Marchi, Lorenzo Fuccio, Vincenzo Savarino, Edoardo Savarino
A human gut ecosystem protects against C. difficile disease by targeting TcdA
Sarah Lynn Martz, Mabel Guzman-Rodriguez, Shu-Mei He, Curtis Noordhof, David John Hurlbut, Gregory Brian Gloor, Christian Carlucci, Scott Weese, Emma Allen-Vercoe, Jun Sun, Erika Chiong Claud, Elaine Olga Petrof
Image assessment of Barrett’s esophagus using the simplified narrow band imaging classification
Masayuki Kato, Kenichi Goda, Yuichi Shimizu, Akira Dobashi, Masakazu Takahashi, Masahiro Ikegami, Tadakazu Shimoda, Mototsugu Kato, Prateek Sharma
Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis
Atsushi Nishida, Hirotsugu Imaeda, Masashi Ohno, Osamu Inatomi, Shigeki Bamba, Mitsushige Sugimoto, Akira Andoh
Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis
Sung-Hoon Moon, Myung-Hwan Kim, Jong Kyun Lee, Seunghee Baek, Young Sik Woo, Dong Hui Cho, Dongwook Oh, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Dong Wan Seo, Sung Koo Lee
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial
Masatoshi Kudo, Etsuro Hatano, Shinichi Ohkawa, Hirofumi Fujii, Akihide Masumoto, Junji Furuse, Yoshiyuki Wada, Hiroshi Ishii, Shuntaro Obi, Shuichi Kaneko, Seiji Kawazoe, Osamu Yokosuka, Masafumi Ikeda, Katsuaki Ukai, Sojiro Morita, Akihito Tsuji, Toshihiro Kudo, Mitsuo Shimada, Yukio Osaki, Ryosuke Tateishi, Gen Sugiyama, Paolo Benjamin Abada, Ling Yang, Takuji Okusaka, Andrew Xiuxuan Zhu
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C
Reona Morio, Michio Imamura, Yoshiiku Kawakami, Kei Morio, Tomoki Kobayashi, Satoe Yokoyama, Yuki Kimura, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, C. Nelson Hayes, Hiroshi Aikata, Shoichi Takahashi, Daiki Miki, Hidenori Ochi, Nami Mori, Shintaro Takaki, Keiji Tsuji, Kazuaki Chayama
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe, Yukio Osaki, Masafumi Ikeda, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Seiichi Hayato, Kiwamu Okita, Hiromitsu Kumada
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
Hiromitsu Kumada, Yoshiyuki Suzuki, Yoshiyasu Karino, Kazuaki Chayama, Norifumi Kawada, Takeshi Okanoue, Yoshito Itoh, Satoshi Mochida, Hidenori Toyoda, Hitoshi Yoshiji, Shintaro Takaki, Naoyoshi Yatsuzuka, Etsuo Yodoya, Takashi Iwasa, Go Fujimoto, Michael N. Robertson, Stuart Black, Luzelena Caro, Janice Wahl